Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

Sponsor
Dana-Farber Cancer Institute
Study ID
NCT05482074
Phase
PHASE2
Status
Withdrawn

Conditions

  • Cutaneous Melanoma
  • Mucosal Melanoma
  • Recurrent Metastatic Melanoma
  • Uveal Melanoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Olaparib — DRUG
    Oral, twice a day, dosage per protocol, per 28 day cycle

Study Details

The purpose of this study is to evaluate how effective Olaparib is when given as a treatment for primary or recurrent, unresectable or metastatic melanoma. This research study involves targeted therapy. -The name of the study drug involved in this study is: Olaparib (also known as Lynparza)

Key Dates

First listed
Aug 1, 2022
Start date
Oct 4, 2022
Status verified
Jan 2024
Primary completion
May 1, 2026
Completion
May 1, 2027

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: OLAPARIB
    The research study procedures include screening for eligibility, study treatment including evaluations, surveys, optional biopsies, and follow up visits Olaparib- Each study treatment cycle lasts 28 days . This will continue for as long as the study treatment is providing clinical benefit

Primary Outcome Measure

Overall response rate (ORR) [ Time Frame: 12 weeks ]

Related Studies